Genital Herpes Information

Famvir Herpes Information herpes at walrus1.walrus.com
Fri Sep 20 16:04:56 EST 1996



*************************************************************************
For further information on Famvir, a full version of the Famvir
press release is available FREE by e-mailing herpes at mcny.com.  
In the subject area please write subscribe herpes your e-mail address.
The information will automatically be sent to you.  To delete your name
please write unsubscribe herpes your e-mail address.
*************************************************************************


Study Shows Famvir Effective For Suppression Of Recurrent Genital Herpes

        NEW ORLEANS, LA, September 18, 1996 -- Patients who suffer from
frequent outbreaks of recurrent genital herpes can significantly benefit
from taking famciclovir  (Famvir, SmithKline Beecham) to prevent these
outbreaks, according to a new study.  The trial results were reported
today by Dr. Francisco Diaz-Mitoma at the 36th annual meeting of the
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
in New Orleans.

        In a multicenter, placebo-controlled trial, the antiviral agent
famciclovir delayed recurrent episodes of genital herpes in patients with
frequently-recurring genital herpes who received 250 mg twice daily
famciclovir for one year (p=0.0001).  Famciclovir extended the median
time to first clinically confirmed lesional episodes from 1.5 months in
the placebo group to up to 11 months in the famciclovir 250 mg twice
daily group.  In addition, the median time to the first culture
documented recurrence was greater than one year for patients in the
famciclovir groups and only 2.7 months for patients in the placebo
group.  The most common reported side effect for famciclovir and placebo
treated patients was headache.

        The incidence of genital herpes, a highly contagious and
recurrent viral infection caused by the herpes simplex virus (HSV) is
increasing globally.  According to the World Health Organization (WHO),
each year there are 21 million new cases of genital herpes worldwide.  In
the United States, it is estimated that 55 million American adults have
genital herpes with 500,000 new cases occurring annually.  In Canada,
approximately 5.8 million people have genital herpes with 50,000 new
cases occurring each year.

        It is estimated that up to 80 percent of patients experience
symptomatic recurrences of genital herpes following an initial outbreak
-- with an average of five recurrences during the year following the
first outbreak.  Patients who experience severe and more frequent
outbreaks may benefit from suppressive therapy (ongoing antiviral
treatment) to prevent outbreaks from recurring.

	Famciclovir is currently indicated for the treatment of recurrent
genital herpes and acute herpes zoster (shingles).  Famciclovir is also
being studied for the treatment of a number of other infections caused by
the viruses belonging to the family of human herpesviruses in both
immunocompetent and immunocompromised individuals.  Studies are also in
progress with this agent in the treatment of chronic hepatitis B virus
infection.

        For further information on Famvir, a full version of the Famvir
press release is available FREE by e-mailing herpes at mcny.com.  In the
subject area please write subscribe herpes your e-mail address.  The
information will automatically be sent to you.  To delete your name
please write unsubscribe herpes your e-mail address.

                                # # #




More information about the Womenbio mailing list